Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Vera Therapeutics ( (VERA) ).
On November 25, 2025, Vera Therapeutics, Inc. appointed James R. Meyers to its board as a Class II Director, with his term expiring at the 2026 Annual Meeting of Stockholders. Meyers will also serve on the Audit Committee and has been granted a stock option to purchase 25,000 shares, with additional compensation including a pro-rated annual cash retainer for 2025. This appointment is part of Vera Therapeutics’ strategy to strengthen its board with experienced leadership, potentially impacting its governance and operational oversight positively.
The most recent analyst rating on (VERA) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Vera Therapeutics stock, see the VERA Stock Forecast page.
Spark’s Take on VERA Stock
According to Spark, TipRanks’ AI Analyst, VERA is a Underperform.
Vera Therapeutics’ overall stock score is driven by ongoing financial challenges, including consistent losses and negative cash flows, despite a strong equity position. Technical analysis indicates bearish momentum, with the stock underperforming key moving averages. The valuation is unattractive due to a negative P/E ratio and no dividend yield.
To see Spark’s full report on VERA stock, click here.
More about Vera Therapeutics
Average Trading Volume: 1,538,835
Technical Sentiment Signal: Buy
Current Market Cap: $1.88B
For detailed information about VERA stock, go to TipRanks’ Stock Analysis page.